Related Experiment Video
Updated: Mar 1, 2026

Development and Validation of a Methodology for Establishing Obese Rat Models with Typical Fatty Pancreas
Published on: November 11, 2025
Translational Modeling to Guide Study Design and Dose Choice in Obesity Exemplified by AZD1979, a
P Gennemark1, M Trägårdh1,2, D Lindén1
1Cardiovascular and Metabolic Diseases, Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Mölndal, Sweden.
Abstract:
In this study, we present the translational modeling used in the discovery of AZD1979, a melanin-concentrating hormone receptor 1 (MCHr1) antagonist aimed for treatment of obesity. The model quantitatively connects the relevant biomarkers and thereby closes the scaling path from rodent to man, as well as from dose to effect level. The complexity of individual modeling steps depends on the quality and quantity of data as well as the prior information; from semimechanistic body-composition models to standard linear regression. Key predictions are obtained by standard forward simulation (e.g., predicting effect from exposure), as well as non-parametric input estimation (e.g., predicting energy intake from longitudinal body-weight data), across species. The work illustrates how modeling integrates data from several species, fills critical gaps between biomarkers, and supports experimental design and human dose-prediction. We believe this approach can be of general interest for translation in the obesity field, and might inspire translational reasoning more broadly.
Related Concept Videos
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Drug Dosing: Obese Patients
Pharmacogenomics: Identification of New Drug Targets
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

